Literature DB >> 15328486

Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease.

Maciej Swiatkowski1, Jacek Budzyński, Maria Kłopocka, Grzegorz Pulkowski, Karol Suppan, Jacek Fabisiak, Włodzimierz Morawski, Marcin Majer.   

Abstract

BACKGROUND: Coronary artery disease (CAD) and gastro-esophageal reflux disease (GERD) often coexist in the same patients. The aim of this study was to estimate the effects of gastric acid output suppression with rabeprazole on course of angina pectoris and results of the treadmill stress test in patients with CAD. MATERIAL/
METHODS: We studied 34 patients with stable angina pectoris. In all subjects a medical history, a physical examination, and a stress test were performed at the beginning of the study and after two weeks of add-on rabeprazole therapy (20 mg b.i.d.).
RESULTS: Rabeprazole therapy significantly improved the outcome of the stress test in 27 patients (79%), prolonging mean stress exercise time (449+/-147 vs. 489+/-156s, p=0.027) and exercise time, leading to a maximum ST interval depression (360+/-167 vs. 467+/-148s, p=0.001), and also decreasing ST interval depression delta (1.9+/-1.1 vs. 1.5+/-0.9; p=0.013).
CONCLUSIONS: In 79% of our study subjects, rabeprazole improved stress test results in CAD patients, which implies that at least some of their symptoms were related to GERD. A proton pump inhibitor exerted a favorable effect on the frequency of angina-like chest pain and the results of the treadmill stress test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328486

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  5 in total

1.  Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey.

Authors:  Jacek Budzyński; Grzegorz Pulkowski; Karol Suppan; Jacek Fabisiak; Marcin Majer; Maria Kłopocka; Beata Galus-Pulkowska; Marcin Wasielewski
Journal:  Health Qual Life Outcomes       Date:  2011-09-22       Impact factor: 3.186

2.  Lipids, blood pressure, kidney - what was new in 2011?

Authors:  Marcin Barylski; Jolanta Małyszko; Jacek Rysz; Michał Myśliwiec; Maciej Banach
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

3.  Treatment with double dose of omeprazole increases β-endorphin plasma level in patients with coronary artery disease.

Authors:  Jacek Budzyński; Grzegorz Pulkowski; Maria Kłopocka; Beata Augustyńska; Anna Sinkiewicz; Karol Suppan; Jacek Fabisiak; Marcin Majer; Maciej Swiątkowski
Journal:  Arch Med Sci       Date:  2010-04-30       Impact factor: 3.318

4.  Acute Coronary Syndrome: An Unusual Consequence of GERD.

Authors:  Chui Man Carmen Hui; Santosh K Padala; Michael Lavelle; Mikhail T Torosoff; Xinjun Cindy Zhu; Mandeep S Sidhu
Journal:  Case Rep Cardiol       Date:  2015-11-24

5.  A review of rabeprazole in the treatment of acid-related diseases.

Authors:  Fabio Pace; Stefano Pallotta; Stefania Casalini; Gabriele Bianchi Porro
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.